mProX™ Human NECTIN4 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

NECTIN4 is a target for antibody-drug conjugates (ADCs) in various applications. In central nervous system (CNS) tumors, ADC target expression is poorly characterized, but NECTIN4 is found to be expressed in most tumors along with other ADC targets such as HER3 and B7-H3. This suggests that clinical trials of ADCs in CNS tumors may be warranted. In prostate cancer, nectin-4 expression was not detected in cancer tissues but was found in benign prostatic gland tissues and atypical small acinar proliferation (ASAP) samples. This indicates a potential relationship between nectin-4 and prostate cancer. In a study on a consanguineous Kashmiri family, a recurrent nonsense mutation in NECTIN4 was found to be associated with ectodermal dysplasia-syndactyly syndrome (EDSS1). This mutation broadens the molecular and phenotypic spectrum of EDSS1. In metastatic urothelial carcinoma (mUC), enfortumab vedotin (EV), an ADC targeting nectin-4, has shown promising results as a single agent and in combination with pembrolizumab. EV has been approved for pre-treated mUC and cisplatin-ineligible naïve mUC patients. Finally, in the clinical development of ADCs, there are opportunities to explore niche indications and targets that have not been extensively studied before, such as enfortumab vedotin in lung or cervical cancer, tisotumab vedotin in glioblastoma or pancreatic cancer, and sacituzumab govitecan in pancreatic, gastric, thyroid, or endometrial cancer. Overall, NECTIN4 plays a significant role as a target for ADCs in various diseases and has potential therapeutic applications.